Children with hiv, sickle cell anemia, aspleniya ...

As of 2010, 3 vaccines for preventing pneumococcal infection in the United States. These vaccines cause antibodies to specific types of pneumococcal capsule. No specific recommendations for use of pneumococcal vaccine in travelers have been formulated. 7-valent pneumococcal conjugated vaccine (PCV7) was part of the routine immunization schedule of children in the United States since 2000. Recommended for all children under 5 years. In 2010, the 13-valent pneumococcal conjugated vaccine (PCV13) was approved by the Administration Food and Drug Administration and replacement of PCV7. PCV13 is recommended to vaccinate all children aged 259 months and for children aged 6071 months with concomitant diseases that increase your risk of pneumococcal infection or complications. Children with HIV, sickle cell anemia, aspleniya, cerebrospinal fluid leak, cochlear implant or can be obtained by PCV13 age 18. PCV7 and PCV13 vaccines are recommended as a 4-dose series at 2 ages 4, 6 and 1215 months. Less than doses required for children who start a series over the age of 7 months. 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for all adults aged 65 years and for people aged 264 years with concomitant diseases. People with basic conditions should be vaccinated as soon as possible after the condition is diagnosed. Children with concomitant diseases that are vaccine should also receive instructions PPSV23, after a series of combined vaccines. Current revaccination with PPSV23 is not recommended for most people. The second dose is recommended 5 years after the first dose for persons with functional or anatomic aspleniya for persons with immunocompromising conditions. People 65 years, who received PPSV23 age of 65 years for the underlying disease should be given another dose of PPSV23, if 5 years have passed since their previous dose. World Health Organization recommends that the inclusion of pneumococcal conjugate vaccine in all national immunization programs should be a priority. As of 2008, 26 industrialized countries are generally used pneumococcal vaccine-related, including USA, Canada, Australia, UK and other countries of Western Europe and the Middle East. 10-valent pneumococcal conjugated vaccine formulation available in many countries, including Europe, Canada and Australia. After receiving PCV7, mild local reactions such as redness, swelling, pain or occur in 10% 23% children. Large field of redness or swelling or limitation of hand movements may occur in 1% 9% of children. Low-grade fever may occur up to 24% and the temperature higher than 102. 2F (39C) may occur in up to 2. 5% of the vaccinated. Profiles of safety and PCV13 PCV7 comparison: the most frequent (20% of recipients) adverse reactions after PCV13 were reactions at the injection site, fever, loss of appetite, irritability, increase or decrease in sleep. After receiving PPV23, local self adverse effects in about half of vaccinated and frequently after revaccination than after the first dose. These reactions usually take place within 48 hours. More severe local reactions and systemic symptoms, including fever and myalgia, are rare. PCV7 is contraindicated in children known to hypersensitivity to any component of the vaccine. PCV13 contraindicated among people known to severe allergic reactions (anaphylaxis) to any component of PCV13 or PCV7 or diphtheria vaccine toxoidcontaining. Clinicians may defer vaccination of children with moderate or severe illness until the child recovered, although minor ailments such as mild upper respiratory tract infection with or without low-grade fever is not a contraindication to vaccination. Revaccination with PPV23 is contraindicated for people who have severe reactions (anaphylactic reaction or localized Arthus-type reaction) in the initial dose. Chemoprophylaxis is generally strattera without prescritpion not recommended for travelers and for close contacts of people with pneumococcal meningitis or other invasive disease cases, unless otherwise recommended by a doctor monitoring their care. .